 |
|
|
| |
High efficacy of glecaprevir/pibrentasvir in patients with chronic HCV GT1 infection who failed prior treatment with NS5A-inhibitor plus sofosbuvir regimens
|
| |
| |
Reported by Jules Levin
The American Association for the Study of Liver Diseases: The Liver Meeting
San Francisco, CA
12 November2018
Mark S. Sulkowski1 , Anna S. Lok 2, Ira Willner, K.3, Rajender Reddy4, Mitchell L. Shiffman5, Mohamed A. Hassan6, Brian L. Pearlman7, Federico Hinestrosa 8,
Ira M. Jacobson9 , Giuseppe Morelli10 , Joy Peter10 , Monika Vainorius11 , Larry Michael11 , Michael W. Fried11 , Gary P. Wang10 , Lois Larsen12 , Jens Kort12 , David R. Nelson10
1 Johns Hopkins University, Baltimore, Maryland; 2 University of Michigan, Ann Arbor, Michigan; 3 Medical University of South Carolina, Charleston, South Carolina; 4 University of Pennsylvania, Philadelphia, Pennsylvania; 5Liver Institute of Virginia, Richmond, Virginia; 6 University of Minnesota, Minneapolis, Minnesota; 7 Wellstar Atlanta Medical Center, Atlanta, GA; 8 Orlando Immunology Center, Orlando, Florida; New York University, New York, New York; 10University of Florida, Gainesville, Florida; 11University of North Carolina, Chapel Hill, North Carolina; 12AbbVie Inc., North Chicago, Illinois
|
| |
|
|
|
|
|
